Financhill
Sell
34

IOBT Quote, Financials, Valuation and Earnings

Last price:
$0.98
Seasonality move :
-21.02%
Day range:
$0.97 - $1.03
52-week range:
$0.66 - $1.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.37x
Volume:
86.1K
Avg. volume:
108.7K
1-year change:
-30%
Market cap:
$64.6M
Revenue:
--
EPS (TTM):
-$1.37

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IOBT
IO Biotech
-- -$0.23 -- -23.33% $9.50
ATNM
Actinium Pharmaceuticals
-- -$0.28 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$1.56 -- -8.25% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IOBT
IO Biotech
$0.98 $9.50 $64.6M -- $0.00 0% --
ATNM
Actinium Pharmaceuticals
$1.67 $5.00 $52.1M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.59 $0.85 $3.4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.41 -- $22.1M -- $0.00 0% --
OGEN
Oragenics
$0.20 $1.00 $4.3M -- $0.00 0% 1.92x
TOVX
Theriva Biologics
$0.56 $7.00 $1.6M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IOBT
IO Biotech
-- -3.128 -- --
ATNM
Actinium Pharmaceuticals
-- -3.541 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IOBT
IO Biotech
-- -$26.5M -- -- -- -$20.8M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

IO Biotech vs. Competitors

  • Which has Higher Returns IOBT or ATNM?

    Actinium Pharmaceuticals has a net margin of -- compared to IO Biotech's net margin of -11511.11%. IO Biotech's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About IOBT or ATNM?

    IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 199.4%. Given that IO Biotech has higher upside potential than Actinium Pharmaceuticals, analysts believe IO Biotech is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is IOBT or ATNM More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.

  • Which is a Better Dividend Stock IOBT or ATNM?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or ATNM?

    IO Biotech quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. IO Biotech's net income of -$24M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, IO Biotech's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns IOBT or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to IO Biotech's net margin of -49.65%. IO Biotech's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About IOBT or NBY?

    IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.07%. Given that IO Biotech has higher upside potential than NovaBay Pharmaceuticals, analysts believe IO Biotech is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is IOBT or NBY More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock IOBT or NBY?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or NBY?

    IO Biotech quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IO Biotech's net income of -$24M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IO Biotech's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns IOBT or NNVC?

    Nanoviricides has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About IOBT or NNVC?

    IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 360.99%. Given that IO Biotech has higher upside potential than Nanoviricides, analysts believe IO Biotech is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is IOBT or NNVC More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock IOBT or NNVC?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or NNVC?

    IO Biotech quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. IO Biotech's net income of -$24M is lower than Nanoviricides's net income of -$2M. Notably, IO Biotech's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    NNVC
    Nanoviricides
    -- -- -- -$2M
  • Which has Higher Returns IOBT or OGEN?

    Oragenics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About IOBT or OGEN?

    IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 400%. Given that IO Biotech has higher upside potential than Oragenics, analysts believe IO Biotech is more attractive than Oragenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    OGEN
    Oragenics
    0 1 0
  • Is IOBT or OGEN More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock IOBT or OGEN?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or OGEN?

    IO Biotech quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. IO Biotech's net income of -$24M is lower than Oragenics's net income of -$2.2M. Notably, IO Biotech's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 1.92x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    OGEN
    Oragenics
    1.92x -- -- -$2.2M
  • Which has Higher Returns IOBT or TOVX?

    Theriva Biologics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About IOBT or TOVX?

    IO Biotech has a consensus price target of $9.50, signalling upside risk potential of 869.39%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1152.68%. Given that Theriva Biologics has higher upside potential than IO Biotech, analysts believe Theriva Biologics is more attractive than IO Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is IOBT or TOVX More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock IOBT or TOVX?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or TOVX?

    IO Biotech quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. IO Biotech's net income of -$24M is lower than Theriva Biologics's net income of -$4.4M. Notably, IO Biotech's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Unity Software a Buy Now?
Is Unity Software a Buy Now?

Unity Software (NYSE:U) is the company behind the popular Unity…

Will Uber Stock 5X?
Will Uber Stock 5X?

Uber (NYSE:UBER) has generated extremely strong returns for its investors…

How High Will Bloom Energy Stock Go?
How High Will Bloom Energy Stock Go?

Bloom Energy (NYSE:BE) has seen its shares surge by more…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
81
SMLR alert for May 17

Semler Scientific [SMLR] is up 28.56% over the past day.

Sell
25
GLOB alert for May 17

Globant SA [GLOB] is down 23.54% over the past day.

Buy
94
HIMS alert for May 17

Hims & Hers Health [HIMS] is up 10.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock